Abstract In this study we evaluated the delayed effects of a calcium entry blocker on blood pressure and on vascular structural and functional alterations in mesenteric resistance arteries of spontaneously hypertensive rats (SHR). The calcium entry blocker nitrendipine was administered (30 mg/kg per day) according to three different schedules: in one group of SHR from 4 to 8 weeks of age (n=12), in a second group from 8 to 12 weeks of age (n=12), and in a third group from 4 to 12 weeks of age (n=12). Twelve untreated SHR and 12 untreated Wistar-Kyoto rats served as controls. Half the animals of each group were killed at 13 weeks, and the remaining were killed at 38 weeks. After death, relative left ventricular mass was calculated. Vascular morphology and function (responses to norepinephrine and acetylcholine) in mesenteric small arteries were then assessed using a micro-
A rteriolar structural alterations have been ob-/ \ served in both hypertensive patients and ani-A.X. mal models of experimental hypertension. 15 These abnormalities include simple media hypertrophy or remodeling 6 and seem to have a significant role in the development and maintenance of hypertension. In fact, vascular structural alterations are associated with an amplification of the effects of several vasoconstricting agents. 78 In addition, an impairment of endothelial function, as evaluated by the vasodilator response to acetylcholine, has been detected in hypertension 912 and may contribute to the imbalance between vasoconstriction and vasodilatation. Accordingly, the prevention or regression of vascular structural alterations should attenuate significantly the development of high blood pressure.
Although several drugs have proved effective in reducing cardiac hypertrophy, data regarding a possible regression of vascular structural and functional alterations by antihypertensive therapy are limited and somewhat controversial.
Cell growth is in large part controlled by peptide and nonpeptide growth factors, among which angiotensin II (Ang II) seems to play a relevant role. 13 Therefore, it is likely that angiotensin-converting enzyme (ACE) inhibitors may exert useful growth regulatory effects.
14 ' 15 In fact, several ACE-inhibitors (captopril, enalapril, cilazapril, perindopril) seem to possess a clear beneficial effect on vascular structure 16 - 21 and were able to determine a more or less prolonged delay in the development or redevelopment of hypertension.
-

22
- 23 These studies suggest the possible existence of a "critical phase" for pharmacologic intervention during the development of hypertension and possible interference with the long-term course of the disease.
Changes in intracellular calcium are intimately involved in the action of Ang II and other growth factors; therefore, calcium entry blockers also would be expected to have favorable effects on vascular structural alterations. In addition, calcium entry blockers may correct the abnormal sensitivity to calcium that has been observed in resistance arteries, at least in the spontaneously hypertensive rat (SHR). 2425 In vitro studies have shown that calcium entry blockers can inhibit the Ang II-induced cell growth to a greater extent than ACE inhibitors (enalapril). 26 On the other hand, the only available study using a calcium entry blocker showed that isradipine had limited effects on vascular structural alterations and did not prevent the development of hypertension after treatment withdrawal. 
M,F In this study we evaluated the delayed effects of nitrendipine, given before or after the development of hypertension, on blood pressure and vascular structural alterations as well as on functional responses to norepinephrine and acetylcholine of mesenteric resistance arteries of SHR.
Methods
Eighty-four rats (60 SHR and 24 Wistar-Kyoto [WKY] rats) were included in the study. Animals were obtained from Charles River Laboratory. All procedures were in accordance with the guidelines of the Medical School, University of Brescia. Rats were housed 2 to a cage in a room in which temperature was controlled between 23° and 25°C, and a 12-hour light/dark cycle was maintained. Food and water were supplied ad libitum.
Nitrendipine was administered at 30 mg/kg per day according to three different schedules: in one group of SHR from 4 to 8 weeks of age (NTD 4-8, n=12), in a second group from 8 to 12 weeks of age (NTD 8-12, n=12), and in a third group from 4 to 12 weeks of age (NTD 4-12, n=12). Twelve SHR and 12 WKY rats were kept untreated as controls. Half the animals of each group were killed at 13 weeks of age, and the remaining were killed at 38 weeks. Two additional groups, each consisting of 6 untreated SHR and 6 WKY rats, were killed at 4 and 8 weeks of age (Fig 1) .
Systolic blood pressure values and heart rate were measured noninvasively (tail-cuff method, IITC Life Science Instruments) in conscious rats every week. In our laboratory the average coefficient of variation of the plethysmographic systolic blood pressure measurement was 5.23% (16 rats, 10 measurements in each rat in a single session).
On the day of death, animals were weighed and then killed by decapitation. The heart was promptly dissected, dried, and weighed. The weight of the left ventricle plus septum was measured, and the relative left ventricular mass (RLVM: left ventricular plus septum weight/body weight) was calculated. average diameter in relaxed conditions, 2 mm long) were obtained by dissection. The vessel segments were excised free of connective and adipose tissue, and two stainless steel wires of 40-jun diameter were threaded through the lumen. This ring preparation was mounted on a micromyograph, as previously described by Mulvany and coworkers. 34 Total time for dissection and preparation was approximately 45 minutes. Vessels were then equilibrated and relaxed for at least 30 minutes in physiological saline solution (PSS) with the following composition (mmol/L): NaCl 119, NaHCO 3 24, KC1 4.7, KH 2 PO 4 1.18, MgSO 4 1.17, CaCI 2 2.5, and glucose 5.5, which was kept constantly at 37°C and bubbled with 5% CO 2 in oxygen. To ensure that relaxation of the arteries was maximal in PSS, Ca 2+ -free PSS was added for approximately 10 minutes and then removed. No further relaxation was observed.
After equilibration, the micromyograph was transferred to the stage of a light microscope with an immersion lens. The vessel was stretched slightly (wall tension approximately 0.1 N/m), and structural characteristics of the vessels were evaluated. The following parameters were measured! thicknesses of the wall, media, adventitia, and intima; internal diameter; media-to-lumen ratio; and media cross-sectional area. Then the normalized internal circumference, L,, was determined, as described previously by Mulvany and coworkers, 3 ' 4 from the resting wall tension-internal circumference relation and the Laplace equation (L, is defined as 0.9 • L loo , where L loo is an estimate of the internal circumference that the vessel would have had in vivo when subjected to a transmural pressure of 100 mm Hg while relaxed). From L,, the normalized internal diameter, I,, was calculated. Assuming that the cross-sectional area remains constant when the vessel is extended to L, (as volume and length of the vessel remain constant), the previously mentioned morphological parameters also were automatically calculated in normalized conditions.
Functional characteristics of the vessels were then evaluated. Vessels were exposed three times to PSS with equimolar exchange of NaCl for KC1 (KPSS) (2 minutes, with a 10-minute interval) to evaluate their response to potassium, the maximal response usually being observed during the third stimulation. The cumulative dose response to norepinephrine was determined by exposing the vessels to increasing concentrations of norepinephrine, with 2 minutes at each concentration. The response to each concentration was measured as the active force at the end of each 2-minute period. Wall tension (active force divided by two times the segment length) and active media stress (wall tension divided by media thickness) were then calculated. Where vessels produced rhythmic activity, the response was measured from the mean active force for the last 20 seconds of each period. The dose-response curve to norepinephrine was performed at the following concentrations: 3 • 10"', 3 • 10-\ 3 • 10" 7 , 1.5 • 10" 6 , 3 • 10" 6 , 1.5 • 10" 5 , and 3 • 10~3 mol/L. Subsequently, a dose-response curve to acetylcholine was performed, after precontraction of the vessels with 3 • 10~6 mol/L norepinephrine and using the previously mentioned criteria, at the following concentrations: 10"', 5 • 10"', 10" 8 , 5
• 10" 8 ,10" 7 , 5 • 10" 7 ,10~\ and 10" 3 mol/L. The response to acetylcholine was expressed as the percent decrease of the active force obtained with norepinephrine precontraction.
Statistical Analysis
All data are expressed as mean±SEM. One-way ANOVA and Bonferroni's correction for multiple comparisons were used to evaluate differences among groups. Two-way ANOVA for repeated measures was used for blood pressure and heart rate (group x time) as well as for dose-response curves to norepinephrine and acetylcholine (group x dose) (programs 7D, IV, and 2V, BMDP Statistical Software Inc).
Results
Blood Pressure
Systolic arterial pressure values in WKY rats and untreated SHR from 4 to 38 weeks are reported in Fig 2. At 4 weeks of age untreated SHR had blood pressure values still in the normal range, whereas at 8 weeks blood pressure was significantly increased (Z'<.001) with respect to WKY rats (Table 1 ). At 13 weeks of age the increase of systolic blood pressure values in untreated SHR with respect to WKY rats was almost fully developed, with a small further increase at 38 weeks. Blood pressure was significantly reduced in all treated groups while drug was administered (on average, 25 to 45 mm Hg less than age-matched, untreated SHR; /><.0001 in any case). After treatment withdrawal, there was a general trend for systolic arterial pressure to increase toward values observed in untreated SHR, but the modalities of this increase were different among the three groups (Fig 2) . Considering the entire posttreatment period, systolic arterial pressure was significantly lower than in untreated SHR controls in the NTD 4-12 and NTD 4-8 groups (ANOVA, / ) <.001) but not in the NTD 8-12 group. In the NTD 4-12 and NTD 4-8 groups systolic arterial pressure remained significantly lower than in untreated SHR up to the 32nd week, that is, 20 to 24 weeks after treatment withdrawal (Fig 2) . In the NTD 8-12 group there was a slightly significant reduction in relative left ventricular mass (LVW/body weight); and definitions as Probability of borderline statistical significance vs untreated SHR is systolic arterial pressure only up to the 17th week, that is, 5 weeks after treatment withdrawal (Fig 2) . Table 2 reports values for heart weight, left ventricular weight, body weight, and RLVM of SHR and WKY rats at different ages. At 4 weeks of age no difference in cardiac mass between untreated SHR and WKY rats was detected, whereas a statistically significant increase of RLVM was observed starting from the eighth week. A significant reduction of RLVM was observed in all groups of treated SHR at 13 weeks but not at 38 weeks. Table 3 reports values for media thickness, wall thickness, media cross-sectional area, internal diameter, and media-lumen ratio of SHR and WKY rats at different ages. Untreated SHR clearly showed the presence of vascular structural alterations at all time points, from 4 to 38 weeks of age. Nitrendipine treatment induced reductions in the media-lumen ratio, media thickness, and wall thickness in all groups, which were detectable at 13 weeks (1 or 5 weeks after treatment withdrawal). At 38 weeks, media and wall thicknesses remained significantly lower in the NTD 4-12 and NTD 4-8 groups with respect to untreated SHR, whereas in the NTD 8-12 group differences were less evident.
Cardiac Morphology
Vascular Morphology
Vascular Function
No significant difference among the groups (WKY rats and untreated and treated SHR) in the response to KPSS or in the sensitivity to norepinephrine as expressed by EQo was observed at any age. In 4-week-old untreated SHR there was an increased response to norepinephrine in terms of wall tension only at the two higher norepinephrine concentrations (maximal wall tension; see Table 4 and Fig 3) . This difference disappeared when active media stress was considered (Table  4) . At both 13 and 38 weeks, wall tension in response to norepinephrine was significantly increased in untreated SHR (ANOVA of dose-response curve, P<.05; Fig 3) . Again, no significant difference between SHR and WKY rats was observed when the functional response was expressed as active media stress (Table 4) .
In treated animals at 13 weeks of age, the regression of vascular structural changes was associated with an almost complete normalization of the dose-response curve to norepinephrine in the NTD 4-12 and NTD 4-8 groups (ANOVA, P<.05 with respect to untreated SHR; P=NS with respect to WKY rats for both), whereas in the NTD 8-12 group, changes in the dose-response curve to norepinephrine were not statistically significant (Fig 3) , possibly reflecting the less-pronounced regression of vascular structural alterations observed in this group at both 13 and 38 weeks. The difference observed at 13 weeks in Table 1. *P<.05, tP<.01 vs untreated SHR. Probability values of borderline statistical significance vs untreated SHR are also reported.
the dose-response curve to norepinephrine between (previously) treated and untreated SHR disappeared at 38 weeks. At 4 weeks of age no significant difference in the dose-response curve to acetylcholine between untreated SHR and WKY rats was observed, whereas at 13 and 38 weeks of age the response to acetylcholine in untreated SHR was significantly (P<.001) reduced with respect to WKY rats (Fig 4, Table 4) . No difference in the dose-response curve to acetylcholine was observed at different ages in WKY rats, whereas a significant (/*<.01) further reduction of endothelial function was observed between 13-and 38-week-old untreated SHR.
At 13 weeks of age the regression of vascular structural alterations was also associated with an almost complete normalization of the dose-response curve to acetylcholine in the NTD 4-12 group (P<.001 with respect to untreated SHR; P=NS with respect to WKY rats) and NTD 8-12 group (P<.01 with respect to untreated SHR; P=NS with respect to WKY rats), whereas in the NTD 4-8 group, changes in the doseresponse curve to acetylcholine were less evident (P<.05 with respect to untreated SHR; P=.O6 with respect to WKY rats) (Fig 4, Table 4 ). In the NTD 4-8 group, treatment was withdrawn 5 weeks before, and systolic blood pressure had gradually risen to high values. The differences in the dose-response curve to acetylcholine between (previously) treated and untreated SHR observed at 13 weeks of age were no longer detectable at 38 weeks.
Discussion
This study shows that short-term treatment with the calcium entry blocker nitrendipine may influence the course of development of hypertension in SHR for several weeks after administration is withdrawn. This finding is similar to what has been observed in different studies on SHR treated with ACE inhibitors, which showed a persistent reduction of blood pressure 12 to 28 weeks after treatment withdrawal. Another similarity between our results and previous studies performed with ACE inhibitors 1820 -23 is the importance of early onset of the treatment. In fact, the development of hypertension was much faster in the group in which treatment started at 8 weeks of age (NTD 8-12) than in the other two groups, in which nitrendipine was administered from the fourth week of age (NTD 4-8 and NTD [4] [5] [6] [7] [8] [9] [10] [11] [12] . On the other hand, the more prolonged treatment in the NTD 4-12 group with respect to the NTD 4-8 group did not result in any significant difference in the time course of posttreatment blood pressure increase.
In the present study, an evident vascular hypertrophy was already present at 4 weeks of age, before any detectable increase of cardiac weight and before the development of hypertension. Although this point is somewhat controversial, several studies have found vascular structural changes very early in SHR (see References 29 and 30 for review). The administration of nitrendipine was associated with the regression of vascular hypertrophy, which was evident in all groups of treated SHR 1 to 5 weeks after treatment withdrawal and maintained over the entire observation period, provided that treatment was started at 4 weeks of age (NTD 4-8 and NTD 4-12). Nitrendipine treatment was also associated with a reduction in cardiac mass in all groups of treated SHR 1 to 5 weeks after treatment withdrawal. This reduction disappeared 26 to 30 weeks after treatment was stopped. This finding may suggest that cardiac mass is more directly influenced by the hemodynamic load than resistance arteries.
The role of blood pressure levels in the development and regression of vascular structural changes in SHR is uncertain. Two findings of the present study would suggest that the influence of blood pressure is of minor if any importance: (1) the presence of an increased media-lumen ratio in 4-week-old prehypertensive SHR compared with WKY rats and (2) the persistence of a significant regression of vascular hypertrophy indexes in the NTD 4-8 and NTD 4-12 groups at 38 weeks, when blood pressure levels in these groups were indistinguishable from those of untreated SHR of the same age. Similar dissociations between vascular structural alterations and blood pressure values were previously observed in one-kidney, one clip rats after unclipping and in SHR after withdrawal of a prolonged Ang II infusion; both models showed a rapid decrease of blood pressure despite a persistent increase of the media-lumen ratio (Mulvany et al, personal communication) . However, in the present study in the NTD 8-12 group, which showed a rapid increase of blood pressure after treatment withdrawal, at the age of 38 weeks the decrease of the media-lumen ratio was no longer statistically significant compared with age-matched, untreated SHR. This observation may be consistent with a possible contribution of long-standing hypertension to the development of vascular hypertrophy in SHR.
Calcium ions act as intracellular messengers mediating a large variety of responses, including cell growth processes.
-
31
- 33 Several substances known as growth regulatory factors, such as Ang II, platelet-derived growth factor, and norepinephrine (a,-pathway), primarily act by binding to membrane receptors with subsequent activation of phosphatidylinositol turnover. The rise in intracellular calcium levels that follows is sometimes simplistically attributed to the mobilization of Ca 2+ from intracellular stores through inositol 1,4,5-trisphosphate; however, it is rather the final result of a complex interaction of different Ca 2+ pools and different Ca 2+ -transporting systems. blockers blunted the Ang II-induced and plateletderived growth factor-induced DNA synthesis in vascular smooth muscle cells and that the inhibitory effect of calcium entry blockers was associated with a marked reduction of the growth factor-induced expression of the immediate-early gene c-fos. M A study from Christensen et al 17 examined the in vivo effects of a calcium entry blocker, isradipine, on vascular structural changes in SHR, showing that early and prolonged treatment with isradipine was associated with a small reduction in the media-lumen ratio and a rapid increase in blood pressure after treatment withdrawal. Our findings with nitrendipine are quite different and seem more similar to the results previously obtained by several groups using ACE inhibitors, vivo growth-suppressing properties of calcium entry blockers appear to be heterogeneous and not necessarily related to the in vitro effects; it cannot be excluded that mechanisms independent of the specific blockade of L-type calcium channels might be involved. 34 It is well known that vascular structural changes in hypertension may act as a vascular amplifier, capable of enhancing any hypertensive stimulus. 7 - 8 We found an increased response to norepinephrine in SHR at all ages, not only during established hypertension but also in a prehypertensive phase, in terms of wall tension but not in terms of active media stress. Similar results are reported in other studies 25 -35 - 36 and clearly suggest that the enhanced response observed in SHR is mainly related to the structural changes present in this strain (ie, media hypertrophy). This conclusion is further supported by the results obtained with nitrendipine treatment, because the treated groups (NTD 4-12 and NTD [4] [5] [6] [7] [8] , in which the reduction of vascular hypertrophy was more pronounced, also showed a more evident trend toward normalization of the dose-response curve to norepinephrine.
The development of hypertension in humans and in animal models of hypertension seems to be associated with an impairment of endothelial functions. 912 Both a reduced synthesis of endothelium-derived relaxing factor/ nitric oxide and/or an enhanced release of endotheliumderived contracting factors might explain the impairment of endothelium-dependent vasodilation observed in SHR after the development of hypertension.
912 Acetylcholine is able to induce the release of endothelium-derived relaxing factor, and therefore the vasodilator response to acetylcholine may be a useful tool in evaluating endothelial function. 9 In the present study, a clear alteration of the vascular response to acetylcholine was observed in 13-and 38-week-old SHR, with respect to WKY rats, whereas in younger SHR before the development of hypertension no difference was present. Similar findings were obtained by Kong et al 36 using a preparation of isolated perfused mesenteric vessels. The biochemical mechanisms underlying endothelial dysfunction are still unclear. In the present study, short-term treatment with nitrendipine determined an almost complete normalization of the dose-response curve to acetylcholine in those rats in which a satisfactory control of blood pressure was obtained up to 1 week before death. On the other hand, in those rats in which therapy was withdrawn 5 weeks before death, the improvement of endothelial alterations was less evident. At 38 weeks of age, when the development or redevelopment of hypertension was completed, no difference in the dose-response curve to acetylcholine between previously treated and untreated SHR was detected despite a persistent significant reduction of structural vascular changes. Moreover, a further worsening of endothelial function was observed from 13 to 38 weeks in untreated SHR, whereas in WKY rats, no impairment of endothelial function with advancing age could be observed. All these findings clearly support the hypothesis that a hemodynamic rather than a structural factor is involved in the genesis of endothelial dysfunction in SHR.
In conclusion, this study shows for the first time the efficacy of a relatively short-term (4 to 8 weeks) treatment with a calcium entry blocker in inducing the regression of structural alterations of mesenteric resistance arteries and the delay of hypertension development in SHR. These favorable effects are maintained for several weeks after treatment withdrawal, provided that treatment is started at 4 weeks of age. Considering the functional alterations of mesenteric arteries in SHR, the enhanced response to norepinephrine appears to be related to the amplifying properties of hypertrophied vessels, whereas the reduced response to acetylcholine is dependent on high blood pressure levels. Nitrendipine treatment determined an improvement of both these dysfunctions, as long as reductions of the medialumen ratio and of blood pressure, respectively, were maintained. D Rizzoni, M Castellano, E Porteri, G Bettoni, M L Muiesan and E Agabiti Rosei Delayed development of hypertension after short-term nitrendipine treatment.
